Form 4: Ocular Therapeutix Executive Chairman Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Pravin Dugel, Executive Chairman, President, and CEO of Ocular Therapeutix, sold 20,880 shares of common stock to cover tax obligations related to vesting restricted stock units.
Summary
- On August 23, 2024, Pravin Dugel, Executive Chairman, President, and CEO of Ocular Therapeutix, sold 20,880 shares of the company's common stock.
- The sale was executed at a weighted average price of $9.02 per share, with individual transactions ranging from $8.88 to $9.14.
- The sale was conducted under a pre-arranged automatic sale instruction adopted on February 21, 2024, to cover tax withholding obligations related to the vesting of restricted stock units on August 22, 2024.
- Following the transaction, Dugel still beneficially owns 812,473 shares of Ocular Therapeutix common stock.
Sentiment
Score: 5
Explanation: The document reports a routine transaction related to tax obligations, which is neither particularly positive nor negative. It's a neutral event in terms of investment sentiment.
Industry Context
Sales of shares to cover tax obligations after vesting of restricted stock units are a common practice among company executives and do not necessarily indicate a negative outlook on the company's future.
Key Dates
| Date | Description |
|---|---|
| 2024-02-21 | Date of adoption of durable automatic sale instruction by the reporting person. |
| 2024-08-22 | Date of vesting of restricted stock units triggering tax withholding obligations. |
| 2024-08-23 | Date of the stock sale transaction. |
| 2024-08-27 | Date of signature of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.